Helix BioPharma Corp. (HBP.TO)
CAD 1.0
(5.26%)
CAD 1.0
(5.26%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -9.37 Million CAD | -49.24% |
| 2023 | -6.27 Million CAD | 3.95% |
| 2022 | -6.53 Million CAD | 31.98% |
| 2021 | -9.61 Million CAD | -11.87% |
| 2020 | -8.59 Million CAD | -14.71% |
| 2019 | -7.48 Million CAD | 12.28% |
| 2018 | -8.53 Million CAD | 16.68% |
| 2017 | -10.24 Million CAD | -6.39% |
| 2016 | -9.63 Million CAD | -10.43% |
| 2015 | -8.72 Million CAD | -0.33% |
| 2014 | -8.69 Million CAD | -6.29% |
| 2013 | -8.17 Million CAD | 22.84% |
| 2012 | -10.59 Million CAD | 15.05% |
| 2011 | -12.47 Million CAD | 6.5% |
| 2010 | -13.34 Million CAD | 5.09% |
| 2009 | -14.05 Million CAD | -73.35% |
| 2008 | -8.11 Million CAD | -20.13% |
| 2007 | -6.75 Million CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -1.82 Million CAD | -102.11% |
| 2024 Q1 | -1.23 Million CAD | 41.94% |
| 2024 Q4 | -5.28 Million CAD | -190.07% |
| 2024 Q2 | -902 Thousand CAD | 27.2% |
| 2023 Q2 | -1.22 Million CAD | 22.54% |
| 2023 Q1 | -1.57 Million CAD | -13.72% |
| 2023 FY | -6.27 Million CAD | 3.95% |
| 2023 Q4 | -2.13 Million CAD | -59.02% |
| 2023 Q3 | -1.34 Million CAD | -10.0% |
| 2022 Q4 | -1.38 Million CAD | -2.29% |
| 2022 Q3 | -1.35 Million CAD | 31.75% |
| 2022 Q2 | -1.98 Million CAD | -9.43% |
| 2022 Q1 | -1.81 Million CAD | 33.76% |
| 2022 FY | -6.53 Million CAD | 31.98% |
| 2021 Q4 | -2.73 Million CAD | -5.92% |
| 2021 FY | -9.61 Million CAD | -11.87% |
| 2021 Q3 | -2.58 Million CAD | -35.71% |
| 2021 Q2 | -1.9 Million CAD | 20.2% |
| 2021 Q1 | -2.38 Million CAD | -17.83% |
| 2020 Q4 | -2.02 Million CAD | 14.34% |
| 2020 FY | -8.59 Million CAD | -14.71% |
| 2020 Q1 | -2.19 Million CAD | -0.09% |
| 2020 Q2 | -2.23 Million CAD | -1.96% |
| 2020 Q3 | -2.36 Million CAD | -5.68% |
| 2019 Q3 | -2.04 Million CAD | -10.04% |
| 2019 Q2 | -1.86 Million CAD | -34.34% |
| 2019 Q1 | -1.38 Million CAD | 13.1% |
| 2019 FY | -7.48 Million CAD | 12.28% |
| 2019 Q4 | -2.19 Million CAD | -6.98% |
| 2018 Q4 | -1.59 Million CAD | 24.76% |
| 2018 FY | -8.53 Million CAD | 16.68% |
| 2018 Q3 | -2.12 Million CAD | 16.34% |
| 2018 Q2 | -2.53 Million CAD | -10.8% |
| 2018 Q1 | -2.28 Million CAD | -72.6% |
| 2017 Q1 | -3.27 Million CAD | -26.04% |
| 2017 FY | -10.24 Million CAD | -6.39% |
| 2017 Q4 | -1.32 Million CAD | 53.82% |
| 2017 Q3 | -2.86 Million CAD | -3.42% |
| 2017 Q2 | -2.77 Million CAD | 15.22% |
| 2016 Q1 | -2.58 Million CAD | -23.01% |
| 2016 Q2 | -2.19 Million CAD | 15.08% |
| 2016 FY | -9.63 Million CAD | -10.43% |
| 2016 Q4 | -2.59 Million CAD | -15.33% |
| 2016 Q3 | -2.25 Million CAD | -2.46% |
| 2015 FY | -8.72 Million CAD | -0.33% |
| 2015 Q4 | -2.1 Million CAD | -11.15% |
| 2015 Q3 | -1.89 Million CAD | 27.59% |
| 2015 Q2 | -2.61 Million CAD | -23.6% |
| 2015 Q1 | -2.11 Million CAD | -17.9% |
| 2014 Q1 | -2.14 Million CAD | -14.98% |
| 2014 Q3 | -2.1 Million CAD | 20.42% |
| 2014 Q4 | -1.79 Million CAD | 14.82% |
| 2014 Q2 | -2.64 Million CAD | -23.08% |
| 2014 FY | -8.69 Million CAD | -6.29% |
| 2013 Q1 | -2.04 Million CAD | -14.28% |
| 2013 FY | -8.17 Million CAD | 22.84% |
| 2013 Q2 | -1.74 Million CAD | 14.74% |
| 2013 Q4 | -1.86 Million CAD | 15.05% |
| 2013 Q3 | -2.2 Million CAD | -25.93% |
| 2012 Q3 | -2.82 Million CAD | 70.06% |
| 2012 Q4 | -1.79 Million CAD | 36.62% |
| 2012 FY | -10.59 Million CAD | 15.05% |
| 2012 Q2 | -9.45 Million CAD | -189.61% |
| 2012 Q1 | -3.26 Million CAD | -27.96% |
| 2011 Q4 | -2.55 Million CAD | 12.91% |
| 2011 FY | -12.47 Million CAD | 6.5% |
| 2011 Q1 | -3.68 Million CAD | 0.0% |
| 2011 Q2 | -3.66 Million CAD | 0.54% |
| 2011 Q3 | -2.92 Million CAD | 20.07% |
| 2010 FY | -13.34 Million CAD | 5.09% |
| 2009 FY | -14.05 Million CAD | -73.35% |
| 2008 FY | -8.11 Million CAD | -20.13% |
| 2007 FY | -6.75 Million CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Appili Therapeutics Inc. | -8.05 Million CAD | -16.407% |
| Eupraxia Pharmaceuticals Inc. | -36.89 Million CAD | 74.602% |
| Microbix Biosystems Inc. | -2.73 Million CAD | -242.453% |
| Medicenna Therapeutics Corp. | -19.66 Million CAD | 52.342% |
| Satellos Bioscience Inc. | -15.46 Million CAD | 39.397% |
| Oncolytics Biotech Inc. | -33.79 Million CAD | 72.268% |
| Sernova Corp. | -41.13 Million CAD | 77.216% |